These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24625823)

  • 1. Trial watch: Bone-building antibody outshines current treatments in osteoporosis trial.
    Harrison C
    Nat Rev Drug Discov; 2014 Apr; 13(4):248. PubMed ID: 24625823
    [No Abstract]   [Full Text] [Related]  

  • 2. Sclerostin Inhibition in the Management of Osteoporosis.
    Appelman-Dijkstra NM; Papapoulos SE
    Calcif Tissue Int; 2016 Apr; 98(4):370-80. PubMed ID: 27016922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Romosozumab: from basic to clinical aspects.
    Minisola S
    Expert Opin Biol Ther; 2014 Sep; 14(9):1225-8. PubMed ID: 24835636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
    Clarke BL
    Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)].
    Quemerais-Durieu MA; Kerlan V; Chabre O
    Ann Endocrinol (Paris); 2011 Oct; 72 Suppl 1():S15-22. PubMed ID: 22008272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anabolic bone therapies in 2014: New bone-forming treatments for osteoporosis.
    Papapoulos SE
    Nat Rev Endocrinol; 2015 Feb; 11(2):69-70. PubMed ID: 25488486
    [No Abstract]   [Full Text] [Related]  

  • 7. New targets for intervention in the treatment of postmenopausal osteoporosis.
    Lewiecki EM
    Nat Rev Rheumatol; 2011 Sep; 7(11):631-8. PubMed ID: 21931340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two pioneering osteoporosis drugs finally approach approval.
    Garber K
    Nat Rev Drug Discov; 2016 Jun; 15(7):445-6. PubMed ID: 27357010
    [No Abstract]   [Full Text] [Related]  

  • 9. [Anti-sclerostin antibodies].
    Okazaki R
    Clin Calcium; 2011 Jan; 21(1):94-8. PubMed ID: 21187600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monoclonal antibodies to sclerostin for the treatment of osteoporosis].
    Soen S
    Clin Calcium; 2013 Jun; 23(6):884-9. PubMed ID: 23719502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
    Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
    Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cathepsin K inhibitors and antisclerostin antibodies. The next treatments for osteoporosis?
    Chapurlat R
    Joint Bone Spine; 2016 May; 83(3):254-6. PubMed ID: 26919802
    [No Abstract]   [Full Text] [Related]  

  • 13. [Innovations in the treatment of osteoporosis].
    Tsourdi E; Hofbauer LC
    Dtsch Med Wochenschr; 2011 Dec; 136(48):2458-60. PubMed ID: 22109575
    [No Abstract]   [Full Text] [Related]  

  • 14. Future directions for new medical entities in osteoporosis.
    Ferrari S
    Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):859-70. PubMed ID: 25432357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies for treating osteoporosis.
    Faienza MF; Chiarito M; D'amato G; Colaianni G; Colucci S; Grano M; Brunetti G
    Expert Opin Biol Ther; 2018 Feb; 18(2):149-157. PubMed ID: 29113523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches to the treatment of osteoporosis.
    Silva BC; Bilezikian JP
    Annu Rev Med; 2011; 62():307-22. PubMed ID: 21054170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting the inhibitor: a new route to bone anabolism.
    Jilka RL
    J Bone Miner Res; 2009 Apr; 24(4):575-7. PubMed ID: 19335216
    [No Abstract]   [Full Text] [Related]  

  • 18. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
    J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: A critical assessment of the mechanism of action.
    Bhattacharyya S; Pal S; Chattopadhyay N
    Eur J Pharmacol; 2018 May; 826():39-47. PubMed ID: 29476877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.
    Li X; Niu QT; Warmington KS; Asuncion FJ; Dwyer D; Grisanti M; Han CY; Stolina M; Eschenberg MJ; Kostenuik PJ; Simonet WS; Ominsky MS; Ke HZ
    Endocrinology; 2014 Dec; 155(12):4785-97. PubMed ID: 25259718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.